Archives: Agenda

• Ensuring your trial is cost-conscious and efficient without compromising on quality or on patient care
• Forecasting and budgeting in order to accurately predict costs and minimize unforeseen expenses
• Keeping your clinical budget on track
• Negotiating prices and contracts in order to ensure maximum benefit without going over budget

MODERATOR
Rene Stephens, Managing Director, Clinical Business Operations, Danforth Advisors

• Analyzing current market dynamics and funding trends shaping biotech growth in 2025
• Addressing ongoing talent shortages and evolving workforce strategies
• Funding and investment for biotechs in and around Boston: how has this shifted in 2025?
• The impact of national political and economic changes on the biotech landscape in Boston and New England

MODERATOR: Gregg Beloff, Founder, Danforth Health

• Understanding Gen AI — Why it matters for clinical operations
• Trends & Barriers — What’s driving adoption or impeding progress
• GenAI in Action — Real world use cases that are transforming clinical ops

• 10 months in: how has the new administration affected the pharma and biotech industry in New England?
• Dealing with change and uncertainty: ensuring your clinical trial timelines stay on track
• Discussing pros and cons of running trials in the US vs overseas considering recent changes
• How have funding and resources been affected in 2025 and how has this impacted outsourcing and clinical operations?

MODERATOR Revati Tatake, Global Head of Pharma Research, Analysis and Competitive Intelligence, GlobalData Healthcare

• Outline critical factors biotech investors evaluate before committing their resources, offering actionable insights to help startups stand out in a competitive market.
• Steps for biotech founders to differentiate, IP strategy and to attract funding
• Avoiding missteps in budgeting and resource allocation together with prioritization and careful planning.
• Storytelling about key milestones achieved aligned with operational activities with feasible exit strategy?
• Does the biotech investor bring strategic expertise beyond capital needs?
• Does the biotech have the appropriate team and expertise to execute?

Visit our exhibitors’ booths throughout the conference and collect stamps in order to enter our Prize Draw and be in for a chance of winning Apple devices or Amazon vouchers. The Prize Draw will take place in the Exhibition Hall, make sure you don’t miss out!

• Optimizing and de-risking trial design and feasibility: how data-driven modeling and simulation tools are helping sponsors design smarter, more efficient trials from the outset
• Enabling in-stream decision-making during execution: using real-time insights to adapt trial operations dynamically, improving quality, timelines, and decision confidence
• AI’s transformative impact on trial delivery: from reshaping how we plan and run trials to redefining roles and workflows, AI is set to re-engineer every stage of clinical development

GlobalData’s clinical trials data indicates that trials initiations in H1 2025 increased significantly over previous years. Public reporting of clinical trials make it easy to miss when and where the real growth is happening. In addition to surprising Wall Street, this has shaken up the competitive landscape and created major opportunities for CROs, CDMOs and Pharma Tech.

• What drove the surge
• Where the next wave is coming from
• How can early signals give you the edge
• Whether you run trials, manufacture at scale, or partner with life sciences companies, this is about being prepared.

• Exploring different funding avenues: how to structure fundraising initiatives
• Working in collaboration with academia: benefits and opportunities
• The importance of building networks and insights from investors in addition to capital
• Lessons learned: analyzing both successes and learnings for future biotech initiatives